Laboratoire de Pathologie Clinique et Unité d'Oncologie, Ecole Nationale Vétérinaire de Lyon, 1 Avenue Bourgelat, 69280 Marcy L'Etoile, France.
Vet Pathol. 2010 May;47(3):414-33. doi: 10.1177/0300985810363902.
This study reports cytomorphological, histomorphological, and immunological characterization of 608 biopsy cases of canine malignant lymphoma, with epidemiological and clinical data, collected from 7 French veterinary pathology laboratories. It compares morphological characteristics of malignant lymphoma in canines, per the updated Kiel classification system, with those reported in humans, per the World Health Organization (WHO) classification system. Of tumors described, 24.5% and 75.5% were classified as low- and high-grade malignant lymphomas, respectively. Presenting clinical signs included generalized or localized lymphadenopathy (82.4%) and extranodal diseases (17.6%) involving the skin (12.34%) and other sites (5.26%). Immunohistochemistry confirmed 63.8% B-cell (CD3-, CD79a+), 35.4% T-cell (CD3+, CD79a-), and 0.8% null-cell (CD3-, CD79a-) lymphomas. Most B-cell cases (38.49%) were of high-grade centroblastic polymorphic subtype; most T-cell cases (8.55%), high-grade pleomorphic mixed and large T-cell lymphoma subtypes. Some B-cell tumors showed morphologic characteristics consistent with follicular lymphomas and marginal zone lymphomas per the Revised European American Classification of Lymphoid Neoplasms and WHO canine classification systems and the WHO human classification system. Unusual high-grade B-cell subtypes included an atypical high-grade small B-cell lymphoma (0.66%), Burkitt-type B-cell lymphoma (1.64%), plasmacytoid lymphoma (0.99%), and mediastinal anaplastic large B-cell lymphoma (0.16%). Unusual T-cell subtypes included a previously undescribed high-grade canine immunoblastic T-cell type (1.15%), a rare low-grade prolymphocytic T-cell lymphoma (0.16%), and a recently described high-grade canine T-cell entity--aggressive granulocytic large-cell lymphoma (0.16%). Marginal zone lymphomas were common (10.86%); follicular lymphomas were rare (0.49%). Canine primary cutaneous malignant lymphoma subtypes were present (11.84%). There was no significant difference between B- and T-cell malignant lymphoma in regard to canine age and sex. A significant overrepresentation of Boxers (24.19%) was found for T-cell lymphomas.
本研究报告了 608 例犬恶性淋巴瘤活检病例的细胞形态学、组织形态学和免疫学特征，并结合 7 家法国兽医病理学实验室收集的流行病学和临床数据进行了分析。该研究将根据更新的 Kiel 分类系统对犬恶性淋巴瘤的形态特征与根据世界卫生组织 (WHO) 分类系统对人类恶性淋巴瘤的形态特征进行了比较。在所描述的肿瘤中，24.5%和 75.5%分别被归类为低级别和高级别恶性淋巴瘤。主要临床表现包括全身性或局部性淋巴结病（82.4%）和结外疾病（17.6%），累及皮肤（12.34%）和其他部位（5.26%）。免疫组织化学证实 63.8%为 B 细胞（CD3-，CD79a+），35.4%为 T 细胞（CD3+，CD79a-），0.8%为无细胞（CD3-，CD79a-）淋巴瘤。大多数 B 细胞病例（38.49%）为高级别中心母细胞多形性亚型；大多数 T 细胞病例（8.55%）为高级别多形混合和大 T 细胞淋巴瘤亚型。一些 B 细胞肿瘤的形态特征符合滤泡性淋巴瘤和边缘区淋巴瘤，根据修订的欧洲-美洲淋巴肿瘤分类和 WHO 犬分类系统以及 WHO 人类分类系统进行分类。不常见的高级别 B 细胞亚型包括非典型高级别小 B 细胞淋巴瘤（0.66%）、伯基特型 B 细胞淋巴瘤（1.64%）、浆母细胞淋巴瘤（0.99%）和纵隔间变性大 B 细胞淋巴瘤（0.16%）。不常见的 T 细胞亚型包括一种以前未描述的高级别犬免疫母细胞 T 细胞类型（1.15%）、一种罕见的低级别前淋巴细胞性 T 细胞淋巴瘤（0.16%）和一种最近描述的高级别犬 T 细胞实体——侵袭性粒细胞性大细胞淋巴瘤（0.16%）。边缘区淋巴瘤很常见（10.86%）；滤泡性淋巴瘤很少见（0.49%）。犬原发性皮肤恶性淋巴瘤亚型也存在（11.84%）。B 细胞和 T 细胞恶性淋巴瘤在犬的年龄和性别方面没有显著差异。T 细胞淋巴瘤中，拳师犬的占比显著较高（24.19%）。
